Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer

Radiotherapy and Oncology

Volumn 91, Issue 3, 2009, Pages 353-359

  De Ruysscher, Dirk ^a   Dehing, Cary ^b   Yu, Shipeng ^c   Wanders, Rinus ^b   Öllers, Michel ^b   Dingemans, Anne Marie C ^a   Bootsma, Gerben ^d   Hochstenbag, Monique ^a   Geraedts, Wiel ^d   Pitz, Cordula ^e   Simons, Jean ^f   Boersma, Liesbeth ^b   Borger, Jacques ^b   Dekker, Andre ^b   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRO CLINIC   (Netherlands)

^c SIEMENS CORPORATE RESEARCH   (United States)

^d Zuyderland Medical Centre   (Netherlands)

^e LAURENTIUS HOSPITAL   (Netherlands)

^f Sint Jans Gasthuis   (Netherlands)

Author keywords

Dyspnea; Lung; NSCLC; Radiopneumonitis; Radiotherapy; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; SCORING SYSTEM; SEX DIFFERENCE; SMOKING HABIT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DYSPNEA; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VINBLASTINE;

EID: 65649089303     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.10.006     Document Type: Article

References (36)

1. Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410 [Abstract]. Proc ASCO 2003:2499.
2. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
3. Saunders M.I., Dische S., Barrett A., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multi-center trial. Radiother Oncol 52 (1999) 137-148
4. Sause W., Kolesar P., Taylor S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group. Chest 117 (2000) 358-364
5. Rosenzweig K.E., Mychalczak B., Fuks Z., et al. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J 6 (2000) 82-87
6. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy update of a phase I trial. J Clin Oncol 19 (2001) 127-136
7. Narayan S., Henning G.T.R.K., Ten Haken R.K., et al. Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer 44 (2004) 79-88
8. Socinski M.A., Morris D.E., Halle J.S., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer a dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350
9. Rosenman J.G., Halle J.S., Socinski M.A., et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54 (2002) 348-356
10. Kong F.M., Ten Haken R.K., Schipper M.J., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 324-333
11. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311 A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
12. Thirion P., Holmberg O., Collins C.D., et al. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol 71 (2004) 163-166
13. Belderbos J., Heemsbergen W., De Jaeger K., et al. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 126-134
14. Saunders B.M.I., Rojas A., Lyn B.E., et al. Experience with Dose Escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy week end less) in non-small cell lung cancer. Br J Cancer 78 (1998) 1323-1328
15. Saunders C.M.I., Rojas A., Lyn B.E., et al. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol 14 (2002) 352-360
16. Rojas D.A.M., Lyn B.E., Wilson E.M., et al. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and three-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Cancer 107 (2006) 1321-1330
17. van Baardwijk A., Bosmans G., Boersma L., et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 71 (2008) 1394-1401
18. De Ruysscher D., Wanders R., van Haren E., et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 71 (2008) 132-138
19. Kong F.M., Hayman J.A., Griffith K.A., et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65 (2006) 1075-1086
20. Madani I., De Ruyck K., Goeminne H., et al. Predicting risk of radiation-induced lung injury. J Thorac Oncol 2 (2007) 864-874
21. Movsas B., Raffin T.A., Epstein A.H., et al. Pulmonary radiation injury. Chest 111 (1997) 1061-1076
22. Kwa S.L., Lebesque J.V., Theuws J.C., et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42 (1998) 1-9
23. Lind P.A., Marks L.B., Hollis D., et al. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys 54 (2002) 340-347
24. Chen S., Zhou S., Yin F.F., et al. Investigation of the support vector machine algorithm to predict lung radiation-induced pneumonitis. Med Phys 34 (2007) 3808-3814
25. Chen S., Zhou S., Yin F.F., et al. Using patient data similarities to predict radiation pneumonitis via a self-organizing map. Phys Med Biol 53 (2008) 203-216
26. Chen S., Zhou S., Zhang J., et al. A neural network model to predict lung radiation-induced pneumonitis. Med Phys 34 (2007) 3420-3427
27. Das S.K., Zhou S., Zhang J., et al. Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees. Int J Radiat Oncol Biol Phys 68 (2007) 1212-1221
28. Ghafoori P., Marks L.B., Vujaskovic Z., et al. Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park) 22 (2008) 37-47
29. Lester J.F., Macbeth F.R., Toy E., et al. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 4 (2006) CD002143
30. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
31. ICRU Report 50. Prescribing, Recording, and reporting Photon Beam Therapy. International Commission on Radiation Units and Measurements. Oxford, UK: Oxford University Press 1993.
32. Nijsten S.M., Mijnheer B.J., Dekker A.L., et al. Routine individualised patient dosimetry using electronic portal imaging devices. Radiother Oncol 83 (2007) 65-75
33. Bentzen S.M., Saunders M.I., and Dische S. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome. Clin Oncol (R Coll Radiol) 14 (2002) 372-381
34. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63 (2005) 5-24
35. Rodrigues G., Lock M., D'Souza D., et al. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer - a systematic review. Radiother Oncol 71 (2004) 127-138
36. Henderson M., McGarry R., Yiannoutsos C., et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys Apr 2 (2008) [Epub ahead of print]